<p>Barrington 分析師 Kevin Steinke 對 CCRN 股票維持中性立場，昨日給予持有評級。</p>
<h3>TipRanks 網絡星期一促銷</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
<p>Kevin Steinke 給予持有評級是由於與 Cross Country Healthcare 最近發展相關的多種因素。與 Aya Healthcare 的合併協議終止，主要是由於對美國聯邦貿易委員會（FTC）可能提出挑戰的擔憂，給公司的戰略方向帶來了不確定性。作為行業的重要參與者，Aya Healthcare 決定退出合併，理由是 FTC 提出的重大競爭擔憂，這可能會對競爭格局產生不利影響。</p>
<p>FTC 的擔憂突顯了醫療人員市場競爭減少的風險，這可能導致醫院和患者的成本上升。儘管 Cross Country 努力遵守監管要求並延長合併協議的時間，但未能最終達成合並使公司不得不繼續獨立運營。這種情況導致了謹慎的前景，最終給予持有評級，因為公司在應對這些挑戰並尋求穩定市場地位。</p>
<p>在昨日發佈的另一份報告中，瑞銀也對該股票維持持有評級，目標價為 9.00 美元。</p>

Cross Country醫療保健

<p>巴林頓分析師凱文·斯坦克（Kevin Steinke）在由於聯邦貿易委員會（FTC）擔憂而終止與 Aya Healthcare 的合併後，維持了對 Cross Country Healthcare（CCRN）股票的持有評級。合併的取消給 CCRN 的戰略方向帶來了不確定性。瑞銀（UBS）也維持了持有評級，目標價為 9.00 美元</p>

<p>Barrington analyst Kevin Steinke has maintained their neutral stance on CCRN stock, giving a Hold rating yesterday.</p>
<div class="lb-trans"><p>Barrington 分析師 Kevin Steinke 對 CCRN 股票維持中性立場，昨日給予持有評級。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 網絡星期一促銷</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
</div><p>Kevin Steinke has given his Hold rating due to a combination of factors surrounding the recent developments with Cross Country Healthcare. The termination of the merger agreement with Aya Healthcare, primarily due to concerns about a potential challenge from the U.S. Federal Trade Commission (FTC), has introduced uncertainty into the company’s strategic direction. Aya Healthcare, being a major player in the industry, decided to withdraw from the merger, citing the significant competitive concerns raised by the FTC, which could have impacted the competitive landscape adversely.</p>
<div class="lb-trans"><p>Kevin Steinke 給予持有評級是由於與 Cross Country Healthcare 最近發展相關的多種因素。與 Aya Healthcare 的合併協議終止，主要是由於對美國聯邦貿易委員會（FTC）可能提出挑戰的擔憂，給公司的戰略方向帶來了不確定性。作為行業的重要參與者，Aya Healthcare 決定退出合併，理由是 FTC 提出的重大競爭擔憂，這可能會對競爭格局產生不利影響。</p>
</div><p>The FTC’s concerns highlighted the risk of reduced competition in the healthcare staffing market, which could have led to higher costs for hospitals and patients. Despite Cross Country’s efforts to comply with regulatory requirements and extend the merger agreement timeline, the inability to finalize the merger has left the company to continue operating independently. This situation has led to a cautious outlook, resulting in a Hold rating as the company navigates these challenges and seeks to stabilize its market position.</p>
<div class="lb-trans"><p>FTC 的擔憂突顯了醫療人員市場競爭減少的風險，這可能導致醫院和患者的成本上升。儘管 Cross Country 努力遵守監管要求並延長合併協議的時間，但未能最終達成合並使公司不得不繼續獨立運營。這種情況導致了謹慎的前景，最終給予持有評級，因為公司在應對這些挑戰並尋求穩定市場地位。</p>
</div><p>In another report released yesterday, UBS also maintained a Hold rating on the stock with a $9.00 price target.</p>
<div class="lb-trans"><p>在昨日發佈的另一份報告中，瑞銀也對該股票維持持有評級，目標價為 9.00 美元。</p>
</div>

Cross Country 醫療保健在終止與 Aya Healthcare 的合併後面臨不確定性